Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Propose...(October 2007. Over the full year cons...),Health

Over the full year, consolidated net sales for the Human Vaccines business rose by 14.5% to euro 2,778 million. Net sales of Menactra(R) advanced by 86.1% to euro 415 million, and net sales of Adacel(TM) increased by 64.5% to euro 234 million. Sanofi pasteur produced over 180 million doses of seasonal influenza vaccines in 2007, reinforcing its position as world leader: the number of doses shipped represented an estimated 40% of the world market(5). Excluding sales of H5N1 vaccines, sales of seasonal influenza vaccines rose by 2.6%.

Change Change

on a on a

Q4 2007 comparable FY 2007 comparable

euro million net sales basis net sales basis

Influenza Vaccines* 245 -40.4% 766 -3.0%

Polio/Pertussis/Hib Vaccines 142 0.0% 660 +5.1%

Meningitis/Pneumonia Vaccines 85 +57.4% 482 +65.1%

Adult Booster Vaccines 70 -2.8% 402 +26.8%

Travel & Other Endemics Vaccines 76 +20.6% 327 +14.7%

Other Vaccines 31 +29.2% 141 +23.7%

TOTAL 649 -15.3% 2,778 +14.5%

* seasonal and pandemic influenza vaccines

Fourth-quarter sales at Sanofi Pasteur MSD, the joint venture with Merck & Co in Europe, rose by 44.4% on a reported basis to euro 371 million, buoyed by the success of Gardasil(R) (net sales of euro 160 million).

Sanofi Pasteur MSD began marketing Gardasil(R) in Europe at the end of 2006. This product, the first vaccine against papillomavirus infections (which cause cervical cancer), is now sold in all 19 European countries covered by the joint venture.

Sanofi Pasteur
'/>"/>